…therapies for patients with rare diseases. More than 70% of rare diseases are known to be caused by a single mutation, which makes them good candidates for gene therapy. Several…
The European Commission has granted marketing authorization to Ranivisio, a treatment for several serious retinal diseases. Polpharma Biologics Group BV, Formycon AG and their Swiss joint venture, Bioeq AG, announced…
Developing effective treatments for neurological diseases is a big challenge in medicine. But here come UCB and Evotec with a new partnership that could help those suffering from epilepsy and…
…are harnessing the unique biology of tRNAs to engineer a single tRNA medicine that could treat thousands of rare diseases that share the same genetic mutation. This year, Alltrna presented…
…own defective cells. The second is in the broader field of drug discovery. Here, iPS cells are being used to explore the underlying causes of human diseases at a molecular…
Clinical-stage pharmaceutical company, Khondrion, discovering and developing therapies targeting primary mitochondrial diseases announced yesterday (November 22) its wholly-owned lead asset sonlicromanol for MELAS spectrum disorder has demonstrated positive treatment results….
…rare disease, with approximately 3.5 million people in the U.K. affected. With more than 7,000 rare diseases identified, there is a need for new treatments and technologies to speed up…
The Dutch biotech Citryll has raised €15M to develop antibodies that could fight autoimmune and inflammatory diseases more effectively than current treatments by inhibiting the innate immune system. The Series…
…development of our scientific platform to address diseases of aging and restore human health.” Life Biosciences tackling range of aging diseases Life Biosciences is advancing its cellular rejuvenation capabilities across…
…biotech companies and investors. Traditionally diseases are ‘underserved’ because they are complex and we don’t understand them well enough, such as some of the more common autoimmune diseases, or because…
ImCheck Therapeutics has raised a Series B round worth €48M to fund the development of first-in-class immunotherapies that treat cancer and autoimmune diseases by targeting a rare type of immune…
…its features. This project could become a powerful new tool to detect anomalies that cause all kinds of diseases. Protein fold assignment is a notoriously tricky area of research in…